Table 4.

One-month point prevalence estimates and 95% confidence intervals for MDE, PTSD, MDE and/or PTSD, and comorbid MDE and PTSD

	Overall, n=120	Male, n=80	Female, n=40	p
MDE case	7.5% (3.7–13.1%), n=9	3.8% (.8–10.6%), n=3	15.0% (6.3–28.1%), n=6	.059
MDE case or subthreshold	25.8% (18.6–34.1%), n=31	26.3% (17.5–36.5%), n=21	25.0% (13.4–39.7%), n=10	.88
PTSD case	10.8% (6.1%-17.2), n=13	10.0% (4.7–17.8%), n=8	12.5% (4.2–26.8%), n=5	.76
PTSD case or subthreshold	20.8% (14.2–28.7%), n=25	21.3% (13.3–31.0%), n=17	20.0% (9.7–34.0%), n=8	.87
MDE and/or PTSD case	14.2% (8.7–21.1%), n=17	10.0% (4.7–17.8%), n=8	22.5% (11.5–36.9%), n=9	.064
MDE and/or PTSD case or subthreshold	36.7% (28.4–45.5%), n=44	35.0% (25.1–45.8%), n=28	40.0% (25.8–55.5%), n=16	.59
Comorbidity (MDE and PTSD case)	4.2% (1.4–9.5%), n=5	3.8% (.8–10.6%), n=3	5.0% (.6–16.9%), n=2	1.00
Comorbidity (MDE and PTSD case or subthreshold)	10.0% (4.6–15.4%), n=12	12.5% (6.5–20.9%), n=10	5.0% (.6–16.9%), n=2	.33

Note. Wald method used for 95% confidence intervals except when n ≤5, in which case exact method was used. Significance testing with chi-square, except any cells had expected count <5, in which case Fisher’s exact test was used.